Free Trial
ASX:BDX

BCAL Diagnostics (BDX) Stock Price, News & Analysis

BCAL Diagnostics logo

About BCAL Diagnostics Stock (ASX:BDX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$36.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

Receive BDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BCAL Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

BDX Stock News Headlines

Elon Warns “America Is Broke”. Trump’s Plan Inside.
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...
See More Headlines

BDX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that BCAL Diagnostics investors own include Chevron (CVX), JPMorgan Chase & Co. (JPM), Bristol-Myers Squibb (BMY), 3M (MMM), NextEra Energy (NEE), ONEOK (OKE) and Tesla (TSLA).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Medical Equipment
Current Symbol
ASX:BDX
CIK
N/A
Fax
N/A
Employees
77,000
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,400,000.00
Net Margins
-295.31%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.10 million
Price / Cash Flow
N/A
Book Value
A$0.03 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$36.60 million
Optionable
Not Optionable
Beta
0.69
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (ASX:BDX) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners